TriStem owns a patented process whereby fully differentiated human cells can be retrodifferentiated into stem cells with the potential to re-differentiate into any other functional cell type, in other words they are multipotent.
This research underlying the procedure has been published in a peer-reviewed journal which can be found here.
TriStem’s technology may be a significant improvement over existing stem cell transplantation for the following key reasons:
- the patient is their own donor, thus negating the need for a donor and immunosuppressant therapy post transplant to avoid rejection, reducing procedure and drug costs;
- the number of stem cells that TriStem is able to generate is greater than is possible by conventional means. Up to 16 billion stem cells can be generated from a single patient in a single procedure over 5-24 hours, compared to 70 million by repeated harvesting over 5-6 weeks, and
- no embryonic or foetal tissues are used in the procedure and there are therefore no ethical issues.
The procedure is non-surgical and uses equipment and techniques that are in routine use in major hospitals world-wide. The procedure can be summarised as follows:
There are several sources for the preparation of stem cells. The following table compares the risks and benefits of the major sources, comparing the features, benefits and risks of each to TriStem’s patented Retrodifferentiation technology.